Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 9:00 PM ET
Mislabel: certepetide Phase 2b ASCEND data, no CRL
Price into the decision (T-120)
Daily close, T-120 (8/7/24) through T+5. Run-up high $3.9 on 1/21/25, low $2.52 on 12/25/24 (T-120 to T-1). FDA decision 1/22/25. Historical price action, not a forecast.
Decision facts
FDA decision date2025-01-22
Outcome✗ CRL⚠ label corrected
Decision-day move-29.5%
T-120 run-up (low→high)+23.0% ($2.43→$3.9)
CRL reasonMislabel: certepetide Phase 2b ASCEND data, no CRL
Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.
Questions
Was source-verified approved by the FDA?
Not in this review cycle. A Complete Response Letter, declining to approve the application for source-verified in its current form, was announced on January 22, 2025. A CRL is not final; the primary source is linked on this page.
How did LSTA stock react to the FDA decision?
On the decision day LSTA moved -29.5%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.